HashKey Group announced that its member, HashKey Europe Limited (“HEL”), had received Virtual Asset Service Provider (VASP) ...
Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for the treatment of diabetic macular edema in October ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback